Critical Reviews™ in Oncogenesis
VOLUME 17 CONTENTS, 2012


ISSUE 1

Special Issue: Part 1: Targeting the Human Kinome for Cancer Therapy
Guest Editor: Roger J. Daly, Ph.D.

Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications
B.N. Rexer & C.L. Arteaga

1

Therapeutic Targeting of BCR-ABL: Prognostic Markers of Response and Resistance Mechanism in Chronic Myeloid Leukaemia
D.T. Yeung & T.P. Hughes

17

Therapeutic Targeting of the Epidermal Growth Factor Receptor in Human Cancer
N.S. Dhomen, J. Mariadason, N. Tebbutt, & A.M. Scott

31

Antiangiogenic Therapies Targeting the Vascular Endothelia Growth Factor Signaling System
J. Tie & J. Desai

51

Targeting PI3 Kinase/AKT/mTOR Signaling in Cancer
K.E. Sheppard, K.M. Kinross, B. Solomon, R.B. Pearson, & W.A. Phillips

69

Aberrant B-Raf Signaling in Human Cancer — 10 Years from Bench to Bedside
M.Röring & T. Brummer

97

ISSUE 2

Special Issue: Part 2: Targeting the Human Kinome for Cancer Therapy
Guest Editor: Roger J. Daly, Ph.D.

Anaplastic Lymphoma Kinase in Human Cancer
C. Schönherr, B. Hallberg, & R.H. Palmer

123

Src Kinase Inhibitors: Promising Cancer Therapeutics?
H.Creedon & V.G. Brunton

145

Targeting the Insulin-like Growth Factor Receptor: Developing Biomarkers from Gene Expression Profiling
D.N. Boone & A.V. Lee

161
### Inhibitors of Cell Cycle Kinases: Recent Advances and Future Prospects as Cancer Therapeutics

A. Stone, R.L. Sutherland, & E.A. Musgrove

Page 175

### FLT3 Signaling and the Development of Inhibitors That Target FLT3 Kinase Activity

W.Y. Langdon

Page 199

### Targeting of EPH Receptor Tyrosine Kinases for Anticancer Therapy

E. Nievergall, T. Saunders, & M.Lackmann

Page 211

### Targeting the Human Kinome for Cancer Therapy: Current Perspectives

L. Zhang & R.J. Daly

Page 233

---

**ISSUE 3**

**Special Issue: Cancer Cachexia, From Basic Research to Clinical Application: A Paradigmatic Translation Research Journey**

**Guest Editor: Professor Giovanni Mantovani**

Page 247

### Neuroinflammation: A Contributing Factor to the Pathogenesis of Cancer Cachexia

A. Laviano, M. Seelaender, S. Rianda, R. Silverio, & F.R. Fanelli

### Counteracting Inflammation: A Promising Therapy in Cachexia

J.M. Argilés, F.J. López-Soriano, & S. Busquets

### Is Tissue Cross-Talk Important in Cancer Cachexia?

N. Johns, C.A. Greig, & K.C.H. Fearon

### Efficacy of Ghrelin in Cancer Cachexia: Clinical Trials and a Novel Treatment by Rikkunshito

N. Fujitsuka, A. Asakawa, H. Amitani, T. Hattori, & A. Inui

### Therapeutic Exercise in Cancer Cachexia

M. Maddocks, A.J. Murton, & A. Wilcock

### The Cachexia Clinic: From Staging to Managing Nutritional and Functional Problems in Advanced Cancer Patients

A.A.L. Vigano, E. Del Fabbro, E. Bruera, & M. Borod

### Multitargeted Treatment of Cancer Cachexia

C. Madeddu, A. Macciò, & G. Mantovani

### Cancer Cachexia: From Molecular Mechanisms to Patient’s Care

S. Lucia, M. Esposito, F.R. Fanelli, & M. Muscaritoli

Page 315
Special Issue: Critical Concepts in the Oncogenesis of Adenocarcinoma of the Rectum
Guest Editor: Dr. Sergio Huerta

Critical Concepts in the Oncogenesis of Adenocarcinoma of the Rectum
S. Huerta

Current Status of Radiation Therapy for the Management of Rectal Cancer
W.G. Rule & J. Meyer

Current Status of Radiosensitizing Agents for the Management of Rectal Cancer
H. Illum

Predictive Biomarkers for Response to Therapy in Advanced Colorectal/Rectal Adenocarcinoma
P. Kapur

Current Status of Surgical Intervention for the Management of Rectal Cancer
C.H. Olson

Biology of Rectal Cancer — The Rationale for Targeted Therapy
S.P. Dineen

New Directions in the Preoperative Management of Adenocarcinoma of the Rectum
S. Huerta